238 related articles for article (PubMed ID: 27765854)
1. Fisetin Enhances Chemotherapeutic Effect of Cabazitaxel against Human Prostate Cancer Cells.
Mukhtar E; Adhami VM; Siddiqui IA; Verma AK; Mukhtar H
Mol Cancer Ther; 2016 Dec; 15(12):2863-2874. PubMed ID: 27765854
[TBL] [Abstract][Full Text] [Related]
2. Cabazitaxel regimens inhibit the growth of prostate cancer cells and enhances the anti-tumor properties of PEDF with various efficacy and toxicity.
Jarvis C; Nelius T; Martinez-Marin D; Sennoune SR; Filleur S
Prostate; 2018 Sep; 78(12):905-914. PubMed ID: 29749077
[TBL] [Abstract][Full Text] [Related]
3. Androgens modify therapeutic response to cabazitaxel in models of advanced prostate cancer.
Begemann D; Wang Y; Yang W; Kyprianou N
Prostate; 2020 Sep; 80(12):926-937. PubMed ID: 32542812
[TBL] [Abstract][Full Text] [Related]
4. Combination of cabazitaxel and p53 gene therapy abolishes prostate carcinoma tumor growth.
Tamura RE; Lana MG; Costanzi-Strauss E; Strauss BE
Gene Ther; 2020 Feb; 27(1-2):15-26. PubMed ID: 30926960
[TBL] [Abstract][Full Text] [Related]
5. Docetaxel/cabazitaxel and fatty acid binding protein 5 inhibitors produce synergistic inhibition of prostate cancer growth.
Carbonetti G; Converso C; Clement T; Wang C; Trotman LC; Ojima I; Kaczocha M
Prostate; 2020 Jan; 80(1):88-98. PubMed ID: 31661167
[TBL] [Abstract][Full Text] [Related]
6. CCL2 induces resistance to the antiproliferative effect of cabazitaxel in prostate cancer cells.
Natsagdorj A; Izumi K; Hiratsuka K; Machioka K; Iwamoto H; Naito R; Makino T; Kadomoto S; Shigehara K; Kadono Y; Lin WJ; Maolake A; Mizokami A
Cancer Sci; 2019 Jan; 110(1):279-288. PubMed ID: 30426599
[TBL] [Abstract][Full Text] [Related]
7. Combination Treatment with Orlistat-Containing Nanoparticles and Taxanes Is Synergistic and Enhances Microtubule Stability in Taxane-Resistant Prostate Cancer Cells.
Souchek JJ; Davis AL; Hill TK; Holmes MB; Qi B; Singh PK; Kridel SJ; Mohs AM
Mol Cancer Ther; 2017 Sep; 16(9):1819-1830. PubMed ID: 28615298
[TBL] [Abstract][Full Text] [Related]
8. Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations.
Li X; Wu JB; Chung LW; Huang WC
Oncotarget; 2015 Dec; 6(38):41018-32. PubMed ID: 26512780
[TBL] [Abstract][Full Text] [Related]
9. Dietary flavonoid fisetin binds to β-tubulin and disrupts microtubule dynamics in prostate cancer cells.
Mukhtar E; Adhami VM; Sechi M; Mukhtar H
Cancer Lett; 2015 Oct; 367(2):173-83. PubMed ID: 26235140
[TBL] [Abstract][Full Text] [Related]
10. Genistein enhances the efficacy of cabazitaxel chemotherapy in metastatic castration-resistant prostate cancer cells.
Zhang S; Wang Y; Chen Z; Kim S; Iqbal S; Chi A; Ritenour C; Wang YA; Kucuk O; Wu D
Prostate; 2013 Nov; 73(15):1681-9. PubMed ID: 23999913
[TBL] [Abstract][Full Text] [Related]
11. A new flavonoid derivative exerts antitumor effects against androgen-sensitive to cabazitaxel-resistant prostate cancer cells.
Naito R; Kano H; Shimada T; Makino T; Kadomoto S; Iwamoto H; Yaegashi H; Izumi K; Kadono Y; Nakata H; Saito Y; Goto M; Nakagawa-Goto K; Mizokami A
Prostate; 2021 Apr; 81(5):295-306. PubMed ID: 33493355
[TBL] [Abstract][Full Text] [Related]
12. GLIPR1-ΔTM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells.
Karanika S; Karantanos T; Kurosaka S; Wang J; Hirayama T; Yang G; Park S; Golstov AA; Tanimoto R; Li L; Thompson TC
Mol Cancer; 2015 Jun; 14():122. PubMed ID: 26084402
[TBL] [Abstract][Full Text] [Related]
13. Testosterone Diminishes Cabazitaxel Efficacy and Intratumoral Accumulation in a Prostate Cancer Xenograft Model.
Mout L; de Wit R; Stuurman D; Verhoef E; Mathijssen R; de Ridder C; Lolkema M; van Weerden W
EBioMedicine; 2018 Jan; 27():182-186. PubMed ID: 29276148
[TBL] [Abstract][Full Text] [Related]
14. Fisetin mediated apoptotic cell death in parental and Oxaliplatin/irinotecan resistant colorectal cancer cells in vitro and in vivo.
Jeng LB; Kumar Velmurugan B; Chen MC; Hsu HH; Ho TJ; Day CH; Lin YM; Padma VV; Tu CC; Huang CY
J Cell Physiol; 2018 Sep; 233(9):7134-7142. PubMed ID: 29574877
[TBL] [Abstract][Full Text] [Related]
15. Suppression of prostate cancer progression by cancer cell stemness inhibitor napabucasin.
Zhang Y; Jin Z; Zhou H; Ou X; Xu Y; Li H; Liu C; Li B
Cancer Med; 2016 Jun; 5(6):1251-8. PubMed ID: 26899963
[TBL] [Abstract][Full Text] [Related]
16. The dietary flavonol fisetin enhances the apoptosis-inducing potential of TRAIL in prostate cancer cells.
Szliszka E; Helewski KJ; Mizgala E; Krol W
Int J Oncol; 2011 Oct; 39(4):771-9. PubMed ID: 21743964
[TBL] [Abstract][Full Text] [Related]
17. Suppression of Taxanes Cytotoxicity by Citrus Flavonoid Hesperetin in PPC-1 Human Prostate Cancer Cells.
Sak K; Lust H; Kase M; Saar M; Jaal J
Anticancer Res; 2018 Nov; 38(11):6209-6215. PubMed ID: 30396939
[TBL] [Abstract][Full Text] [Related]
18. Novel actions of next-generation taxanes benefit advanced stages of prostate cancer.
de Leeuw R; Berman-Booty LD; Schiewer MJ; Ciment SJ; Den RB; Dicker AP; Kelly WK; Trabulsi EJ; Lallas CD; Gomella LG; Knudsen KE
Clin Cancer Res; 2015 Feb; 21(4):795-807. PubMed ID: 25691773
[TBL] [Abstract][Full Text] [Related]
19. Molecular Mechanism Mediating Cytotoxic Activity of Cabazitaxel in Docetaxel-resistant Human Prostate Cancer Cells.
Watanabe H; Kawakami A; Sato R; Watanabe K; Matsushita Y; Miyake H
Anticancer Res; 2021 Aug; 41(8):3753-3758. PubMed ID: 34281834
[TBL] [Abstract][Full Text] [Related]
20. Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors.
Thomas C; Wafa LA; Lamoureux F; Cheng H; Fazli L; Gleave ME; Rennie PS
Prostate; 2012 Jun; 72(8):875-85. PubMed ID: 22072572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
